Shenzhen, May 14, 2025 (GLOBE NEWSWIRE) -- MicroAlgo Inc. Announces Research on Quantum Information Recursive Optimization (QIRO) Algorithm, for Combinatorial Optimization Problems to Expand and Solve ...
Recursion is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Central to its mission is the Recursion Operating System (OS), a platform built across diverse ...
SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...
Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will ...
Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...
Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...
The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback